口服扇贝衍生的缩醛磷脂(sPlas)可显著改善阿尔茨海默病(AD)患者的认知功能。
然而,sPlas对慢性脑低灌注(CCH)AD的影响及其机制,一类混合型痴呆症在痴呆症社会中占20-30%,仍然难以捉摸。
在本研究中,我们应用了一种新型的带有CCH的AD小鼠模型来研究sPlas对带有CCH的AD的潜在影响。
本研究表明sPlas显著恢复了脑血流量,改善运动和认知缺陷,β淀粉样蛋白病理减少,调节神经炎症,改善神经氧化应激,并在12μM下抑制CCH小鼠的AD中的神经元损失。
这些发现表明,在新型模型小鼠中,sPlas对带有CCH的AD具有临床和病理学益处。此外,sPlas对患有CCH的AD患者具有良好的预防和治疗作用。
The oral ingestion of scallop-derived plasmalogen (sPlas) significantly improved cognitive function in Alzheimer\'s disease (AD) patients.
However, the effects and mechanisms of sPlas on AD with chronic cerebral hypoperfusion (CCH), a class of mixed dementia contributing to 20-30% among the dementia society, were still elusive.
In the present study, we applied a novel mouse model of AD with CCH to investigate the potential effects of sPlas on AD with CCH.
The present study demonstrated that sPlas significantly recovered cerebral blood flow, improved motor and cognitive deficits, reduced amyloid-β pathology, regulated neuroinflammation, ameliorated neural oxidative stress, and inhibited neuronal loss in AD with CCH mice at 12 M.
These findings suggest that sPlas possesses clinical and pathological benefits for AD with CCH in the novel model mice. Furthermore, sPlas could have promising prevention and therapeutic effects on patients of AD with CCH.